SCHEMBL6390992

SCHEMBL6390992

NC(=O)N(CCC1SC(NC2CCCCCC2)=NC1=O)c1c(F)cccc1F

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.33
KMT2A Q03164 4/20 0.32
MEN1 O00255 3/20 0.32
FFAR4 Q5NUL3 1/20 0.32
GAA P10253 1/20 0.32
POLB P06746 1/20 0.31
EPHX1 P07099 1/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
CHEK1 O14757 3/20 0.31
KCNH2 Q12809 1/20 0.31
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP2C19 P33261 1/20 0.31
FER P16591 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6427397 0.85 NPC1 (0.35) JAK2POLBNPC1RAB9ACHEK1
SCHEMBL6499658 0.81 CXCR2 (0.36) KMT2AMEN1POLBNPC1RAB9A
SCHEMBL6428935 0.80 EPHX2 (0.36) JAK2NPC1RAB9A
SCHEMBL6386566 0.80 MEN1 (0.40) KMT2AMEN1GAAPOLBNPC1
SCHEMBL6394447 0.77 KDM4E (0.31) KMT2AMEN1ALDH1A1
SCHEMBL6388703 0.77 CCNA2 (0.41) KMT2APOLBNPC1RAB9AADORA2A
SCHEMBL6390900 0.77 CCNA2 (0.41) KMT2APOLBNPC1RAB9AADORA2A
SCHEMBL6392368 0.77 CCNA2 (0.41) KMT2APOLBNPC1RAB9AADORA2A
SCHEMBL6388633 0.77 MEN1 (0.46) KMT2AMEN1POLBNPC1RAB9A
SCHEMBL6388630 0.76 SMN1; SMN2 (0.41) JAK2KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 JAK2 4247/4885KMT2A 3213/4885MEN1 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.